Gentamicin Injection USP

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Injection, USP and other antibacterial drugs, Gentamicin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
BOXED WARNINGS

Patients treated with aminoglycosides should be under close clinical observation because of the potential toxicity associated with their use.

As with other aminoglycosides, Gentamicin Injection is potentially nephrotoxic. The risk of nephrotoxicity is greater in patients with impaired renal function and in those who receive high dosage or prolonged therapy.

Neurotoxicity manifested by ototoxicity, both vestibular and auditory, can occur in patients treated with gentamicin, primarily in those with pre-existing renal damage and in patients with normal renal function treated with higher doses and/or for longer periods than recommended. Aminoglycoside-induced ototoxicity is usually irreversible. Other manifestations of neurotoxicity may include numbness, skin tingling, muscle twitching and convulsions.

Renal and eighth cranial nerve function should be closely monitored, especially in patients with known or suspected reduced renal function at onset of therapy, and also in those whose renal function is initially normal but who develop signs of renal dysfunction during therapy. Urine should be examined for decreased specific gravity, increased excretion of protein, and the presence of cells or casts. Blood urea nitrogen (BUN), serum creatinine, or creatinine clearance should be determined periodically. When feasible, it is recommended that serial audiograms be obtained in patients old enough to be tested, particularly high-risk patients. Evidence of ototoxicity (dizziness, vertigo, tinnitus, roaring in the ears or hearing loss) or nephrotoxicity requires dosage adjustment or discontinuance of the drug. As with the other aminoglycosides, on rare occasions changes in renal and eighth cranial nerve function may not become manifest until soon after completion of therapy.

Serum concentrations of aminoglycosides should be monitored when feasible to assure adequate levels and to avoid potentially toxic levels. When monitoring gentamicin peak concentrations, dosage should be adjusted so that prolonged levels above 12 mcg/mL are avoided.

When monitoring gentamicin trough concentrations, dosage should be adjusted so that levels above 2 mcg/mL are avoided. Excessive peak and/or trough serum concentrations of aminoglycosides may increase the risk of renal and eighth cranial nerve toxicity. In the event of overdose or toxic reactions, hemodialysis may aid in the removal of gentamicin from the blood, especially if renal function is, or becomes, compromised. The rate of removal of gentamicin is considerably less by peritoneal dialysis than by hemodialysis.

In the newborn infant, exchange transfusions may also be considered.

Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as cisplatin, cephaloridine, kanamycin, amikacin, neomycin, polymyxin B, colistin, paromomycin, streptomycin, tobramycin, vancomycin, and viomycin, should be avoided. Other factors which may increase patient risk of toxicity are advanced age and dehydration.

The concurrent use of gentamicin with potent diuretics, such as ethacrynic acid or furosemide, should be avoided, since certain diuretics by themselves may cause ototoxicity. In addition, when administered intravenously, diuretics may enhance aminoglycoside toxicity by altering the antibiotic concentration in serum and tissue.

Aminoglycosides can cause fetal harm when administered to a pregnant woman (see WARNINGS section).

DESCRIPTION:

Gentamicin sulfate, a water-soluble antibiotic of the aminoglycoside group, is derived from Micromonospora purpurea, an actinomycete.
It has the following structural formula:

Gentamicin Injection is a sterile, nonpyrogenic, aqueous solution for parenteral administration.

Each mL of the preserved product contains: Gentamicin sulfate equivalent to gentamicin 10 mg; methylparaben 1.3 mg and propylparaben 0.2 mg as preservatives; sodium metabisulfite 3.2 mg; edetate disodium 0.1 mg; Water for Injection q.s. Sulfuric acid and/or sodium hydroxide may have been added for pH adjustment (3.0 to 5.5).

**CLINICAL PHARMACOLOGY:**

After intramuscular administration of gentamicin sulfate, peak serum concentrations usually occur between 30 and 60 minutes and serum levels are measurable for 6 to 8 hours. In infants, a single dose of 2.5 mg/kg usually provides a peak serum level in the range of 3 to 5 mcg/mL. When gentamicin is administered by intravenous infusion over a two-hour period, the serum concentrations are similar to those obtained by intramuscular administration. Age markedly affects the peak concentrations; in one report, a 1 mg/kg dose produced mean peak concentrations of 1.58, 2.03, and 2.81 mcg/mL in patients six months to five years old, 5 to 10 years old, and over 10 years old, respectively.

In infants one week to six months of age, the half-life is 3 to 3 ½ hours. In full-term and large premature infants less than one week old, the approximate serum half-life of gentamicin is 5 ½ hours. In small premature infants, the half-life is inversely related to birth weight. In premature infants weighing less than 1,500 grams, the half-life is 11 ½ hours; in those weighing 1,500 to 2,000 grams, the half-life is eight hours; in those weighing over 2,000 grams, the half-life is approximately five hours. While some variation is to be expected due to a number of variables such as age, body temperature, surface area and physiologic differences, the individual patient given the same dose tends to have similar levels in repeated determinations.

Gentamicin, like all aminoglycosides, may accumulate in the serum and tissues of patients treated with higher doses and/or for prolonged periods, particularly in the presence of impaired or immature renal function. In patients with immature or impaired renal function, gentamicin is cleared from the body more slowly than in patients with normal renal function. The more severe the impairment, the slower the clearance. (Dosage must be adjusted.)

Since gentamicin is distributed in extracellular fluid, peak serum concentrations may be lower than usual in patients who have a large volume of this fluid. Serum concentrations of gentamicin in febrile patients may be lower than those in afebrile patients given the same dose. When body temperature returns to normal, serum concentrations of the drug may rise. Febrile and anemic states may be associated with a shorter than usual serum half-life. (Dosage adjustment is usually not necessary.) In severely burned patients, the half-life may be significantly decreased and resulting serum concentrations may be lower than anticipated from the mg/kg dose.

Protein-binding studies have indicated that the degree of gentamicin binding is low, depending upon the methods used for testing, this may be between 0 and 30%.

In neonates less than three days old, approximately 10% of the administered dose is excreted in 12
hours; in infants 5 to 40 days old, approximately 40% is excreted over the same period. Excretion of gentamicin correlates with postnatal age and creatinine clearance. Thus, with increasing postnatal age and concomitant increase in renal maturity, gentamicin is excreted more rapidly. Little, if any, metabolic transformation occurs; the drug is excreted principally by glomerular filtration. After several days of treatment, the amount of gentamicin excreted in the urine approaches, but does not equal, the daily dose administered. As with other aminoglycosides, a small amount of the gentamicin dose may be retained in the tissues, especially in the kidneys. Minute quantities of aminoglycosides have been detected in the urine of some patients weeks after drug administration was discontinued. Renal clearance of gentamicin is similar to that of endogenous creatinine.

In patients with marked impairment of renal function, there is a decrease in the concentration of aminoglycosides in urine and in their penetration into defective renal parenchyma. This decreased drug excretion, together with the potential nephrotoxicity of aminoglycosides, should be considered when treating such patients who have urinary tract infections.

Probenecid does not affect renal tubular transport of gentamicin.

The endogenous creatinine clearance rate and the serum creatinine level have a high correlation with the half-life of gentamicin in serum. Results of these tests may serve as guides for adjusting dosage in patients with renal impairment (see DOSAGE AND ADMINISTRATION).

Following parenteral administration, gentamicin can be detected in serum, lymph, tissues, sputum, and in pleural, synovial, and peritoneal fluids. Concentrations in renal cortex sometimes may be eight times higher than the usual serum levels. Concentrations in bile, in general, have been low and have suggested minimal biliary excretion. Gentamicin crosses the peritoneal as well as the placental membranes. Since aminoglycosides diffuse poorly into the subarachnoid space after parenteral administration, concentrations of gentamicin in cerebrospinal fluid are often low and dependent upon dose, rate of penetration, and degree of meningeal inflammation. There is minimal penetration of gentamicin into ocular tissues following intramuscular or intravenous administration.

**Microbiology**

*Mechanism of Action*

Gentamicin, an aminoglycoside, binds to the prokaryotic ribosome, inhibiting protein synthesis in susceptible bacteria. It is bactericidal *in vitro* against Gram-positive and Gram-negative bacteria.

*Mechanism of Resistance*

Bacterial resistance to gentamicin is generally developed slowly. Bacteria resistant to one aminoglycoside may be resistant to one or more other aminoglycosides. The following bacteria are usually resistant to the aminoglycosides, including gentamicin: most streptococcal species (including *Streptococcus pneumoniae* and the Group D streptococci), most enterococcal species (including *Enterococcus faecalis, E. faecium*, and *E. durans*), and anaerobic organisms, such as *Bacteroides* species and *Clostridium* species.

Aminoglycosides are known to be not effective against *Salmonella* and *Shigella* species in patients. Therefore, *in vitro* susceptibility test results should not be reported.

*Interactions with Other Antimicrobials*

*In vitro* studies show that an aminoglycoside combined with an antibiotic that interferes with cell wall synthesis may act synergistically against some enterococcal strains. The combination of gentamicin and penicillin G has a synergistic bactericidal effect against strains of *Enterococcus faecalis, E. faecium* and *E. durans*. An enhanced killing effect against many of these strains has also been shown *in vitro* with combinations of gentamicin and ampicillin, carbenicillin, nafcillin or oxacillin.

The combined effect of gentamicin and carbenicillin is synergistic for many strains of *Pseudomonas aeruginosa*. *In vitro* synergism against other Gram-negative organisms has been shown with combinations of gentamicin and cephalosporins.
Gentamicin may be active against clinical isolates of bacteria resistant to other aminoglycosides.

*Antibacterial Activity*

Gentamicin has been shown to be active against most of the following bacteria, both *in vitro* and in clinical infections (see **INDICATIONS AND USAGE**).

**Gram-Positive Bacteria**

*Staphylococcus* species

**Gram-Negative Bacteria**

*Citrobacter* species

*Enterobacter* species

*Escherichia coli*

*Klebsiella* species

*Proteus* species

*Serratia* species

*Pseudomonas aeruginosa*

**Susceptibility Test Methods**

When available, the clinical microbiology laboratory should provide cumulative results of the *in vitro* susceptibility tests for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antimicrobial drug for treatment.

**Dilution Technique**

Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method. Standardized procedures are based on a dilution method (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of gentamicin powder. The MIC values should be interpreted according to the criteria provided in Table 1.

**Diffusion Technique**

Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized test method. The standardized procedure requires the use of standardized inoculum concentrations and paper disks impregnated with 10 mcg of gentamicin. The disk diffusion values should be interpreted according to the criteria provided in Table 1.

**Table 1: Susceptibility Interpretive Criteria for Gentamicin**

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>Susceptibility Interpretive Criteria</th>
<th>Zone Diameter (mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Minimal Inhibitory Concentration (mcg/mL)</td>
<td>(S)</td>
</tr>
<tr>
<td><em>Enterobacteriaceae</em></td>
<td>≤4</td>
<td>8</td>
</tr>
<tr>
<td><em>Pseudomonas aeruginosa</em></td>
<td>≤4</td>
<td>8</td>
</tr>
<tr>
<td><em>Staphylococcus</em></td>
<td>≤4</td>
<td>8</td>
</tr>
</tbody>
</table>
Species

S = Susceptible, I = Intermediate, R = Resistant

*a* For *Salmonella* and *Shigella* spp., aminoglycosides may appear active *in vitro* but are not effective clinically; the results should not be reported as susceptible

*b* For staphylococci that test susceptible, aminoglycosides are used only in combination with other active agents that test susceptible

A report of *Susceptible (S)* indicates that the antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentration usually achievable at the infection site necessary to inhibit growth of the pathogen. A report of *Intermediate (I)* indicates that the result should be considered equivocal, and if the microorganism is not fully susceptible to alternative clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of the drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of *Resistant (R)* indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the infection site; other therapy should be selected.

**Quality Control**

Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individuals performing the test. Standard gentamicin powder should provide the following range of MIC values provided in Table 2. For the diffusion technique using the 10-mcg gentamicin disk the criteria provided in Table 2 should be achieved.

| Table 2: Acceptable Quality Control Ranges for Gentamicin |
|-----------------|-----------------|-----------------|
| **Quality Control Organism** | **Minimum Inhibitory Concentrations (mcg/mL)** | **Zone Diameter (mm)** |
| *Escherichia coli* ATCC 25922 | 0.25 to 1 | 19 to 26 |
| *Pseudomonas aeruginosa* ATCC 27853 | 0.5 to 2 | 17 to 23 |
| *Staphylococcus aureus* ATCC 25923 | Not Applicable | 19 to 27 |
| *Staphylococcus aureus* ATCC 29213 | 0.12 to 1 | Not Applicable |
| *Enterococcus faecalis* ATCC 29212 | 4 to 16 | Not Applicable |

Note: For control organisms for gentamicin high-level aminoglycoside screen tests for enterococci, see Table 3

**INDICATIONS AND USAGE:**

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Injection, USP and other antibacterial drugs, Gentamicin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may
contribute to the empiric selection of therapy.

Gentamicin Injection is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: *Pseudomonas aeruginosa*, *Proteus* species (indole-positive and indole-negative), *Escherichia coli*, *Klebsiella-Enterobacter-Serratia* species, *Citrobacter* species, and *Staphylococcus* species (coagulase-positive and coagulase-negative).

Clinical studies have shown Gentamicin Injection to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity.

Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin.

Gentamicin may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the BOXED WARNINGS above. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted.

In serious infections when the causative organisms are unknown, gentamicin may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued.

Gentamicin has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by *Pseudomonas aeruginosa*. It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci.

Gentamicin Injection has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms.

In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin.

**CONTRAINDICATIONS:**

Hypersensitivity to gentamicin is a contraindication to its use. A history of hypersensitivity or serious toxic reactions to other aminoglycosides may contraindicate use of gentamicin because of the known cross-sensitivity of patients to drugs in this class.

**WARNINGS:**

(See BOXED WARNINGS.)

Preserved Gentamicin Injection contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic
Aminoglycosides can cause fetal harm when administered to a pregnant woman. Aminoglycoside antibiotics cross the placenta, and there have been several reports of total irreversible bilateral congenital deafness in children whose mothers received streptomycin during pregnancy. Serious side effects to mother, fetus, or newborn have not been reported in the treatment of pregnant women with other aminoglycosides. Animal reproduction studies conducted on rats and rabbits did not reveal evidence of impaired fertility or harm to the fetus due to gentamicin sulfate.

It is not known whether gentamicin sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. If gentamicin is used during pregnancy or if the patient becomes pregnant while taking gentamicin, she should be apprised of the potential hazard to the fetus.

PRECAUTIONS:

General

Prescribing Gentamicin Injection in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Neurotoxic and nephrotoxic antibiotics may be almost completely absorbed from body surfaces (except the urinary bladder) after local irrigation and after topical application during surgical procedures. The potential toxic effects of antibiotics administered in this fashion (neuromuscular blockade, respiratory paralysis, oto- and nephrotoxicity) should be considered (see BOXED WARNINGS).

Increased nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporins.

Neuromuscular blockade and respiratory paralysis have been reported in the cat receiving high doses (40 mg/kg) of gentamicin. The possibility of these phenomena occurring in man should be considered if aminoglycosides are administered by any route to patients receiving anesthetics, or to patients receiving neuromuscular blocking agents, such as succinylcholine, tubocurarine or decamethonium, or in patients receiving massive transfusions of citrate-anticoagulated blood. If neuromuscular blockade occurs, calcium salts may reverse it.

Aminoglycosides should be used with caution in patients with neuromuscular disorders, such as myasthenia gravis, since these drugs may aggravate muscle weakness because of their potential curare-like effects on the neuromuscular junction. During or following gentamicin therapy, paresthesias, tetany, positive Chvostek and Trousseau signs, and mental confusion have been described in patients with hypomagnesemia, hypocalcemia, and hypokalemia. When this has occurred in infants, tetany and muscle weakness have been described. Both adults and infants required appropriate corrective electrolyte therapy.

A Fanconi-like syndrome, with amino-aciduria and metabolic acidosis, has been reported in some adults and infants being given gentamicin injections.

Cross-allergenicity among aminoglycosides has been demonstrated.

Patients should be well hydrated during treatment.

Although the in vitro mixing of gentamicin and carbenicillin results in a rapid and significant inactivation of gentamicin, this interaction has not been demonstrated in patients with normal renal function who received both drugs by different routes of administration. A reduction in gentamicin serum half-life has been reported in patients with severe renal impairment receiving carbenicillin concomitantly with gentamicin.

Treatment with gentamicin may result in overgrowth of nonsusceptible organisms. If this occurs, appropriate therapy is indicated.
Do not administer unless solution is clear and package undamaged.

See **BOXED WARNINGS** regarding concurrent use of potent diuretics and regarding concurrent and/or sequential use of other neurotoxic and/or nephrotoxic antibiotics and for other essential information.

**Information for Patients**

Patients should be counseled that antibacterial drugs including Gentamicin Injection should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Gentamicin Injection is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Gentamicin Injection or other antibacterial drugs in the future.

**Pregnancy Category D**

See **WARNINGS** section.

**ADVERSE REACTIONS:**

**Nephrotoxicity**

Adverse renal effects, as demonstrated by the presence of casts, cells, or protein in the urine or by rising BUN, NPN, serum creatinine or oliguria, have been reported. They occur more frequently in patients treated for longer periods or with larger dosages than recommended.

**Neurotoxicity**

Serious adverse effects on both vestibular and auditory branches of the eighth nerve have been reported, primarily in patients with renal impairment (especially if dialysis is required), and in patients on high doses and/or prolonged therapy. Symptoms include dizziness, vertigo, tinnitus, roaring in the ears and hearing loss, which, as with other aminoglycosides, may be irreversible. Hearing loss is usually manifested initially by diminution of high-tone acuity. Other factors which may increase the risk of toxicity include excessive dosage, dehydration and previous exposure to other ototoxic drugs. Peripheral neuropathy or encephalopathy, including numbness, skin tingling, muscle twitching, convulsions and a myasthenia gravis-like syndrome, have been reported.

**Note:** The risk of toxic reactions is low in neonates, infants and children with normal renal function who do not receive Gentamicin Injection at higher doses or for longer periods of time than recommended.

Other reported adverse reactions possibly related to gentamicin include: respiratory depression, lethargy, confusion, depression, visual disturbances, decreased appetite, weight loss, hypotension and hypertension; rash, itching, urticaria, generalized burning, laryngeal edema, anaphylactoid reactions, fever and headache; nausea, vomiting, increased salivation and stomatitis; purpura, pseudotumor cerebri, acute organic brain syndrome, pulmonary fibrosis, alopecia, joint pain, transient hepatomegaly and splenomegaly.

Laboratory abnormalities possibly related to gentamicin include: increased levels of serum transaminase (SGOT, SGPT), serum LDH and bilirubin, decreased serum calcium, magnesium, sodium and potassium; anemia, leukopenia, granulocytopenia, transient agranulocytosis, eosinophilia, increased and decreased reticulocyte counts and thrombocytopenia. While clinical laboratory test abnormalities may be isolated findings, they may also be associated with clinically related signs and symptoms. For example, tetany and muscle weakness may be associated with hypomagnesemia, hypocalcemia, and hypokalemia.

While local tolerance of Gentamicin Injection is generally excellent, there has been an occasional
report of pain at the injection site. Subcutaneous atrophy or fat necrosis suggesting local irritation has been reported rarely.

OVERDOSAGE:

In the event of overdose or toxic reactions, hemodialysis may aid in the removal of gentamicin from the blood, and is especially important if renal function is, or becomes, compromised. The rate of removal of gentamicin is considerably less by peritoneal dialysis than it is by hemodialysis. In the newborn infant, exchange transfusions may also be considered.

DOSAGE AND ADMINISTRATION:

Gentamicin Injection may be given intramuscularly or intravenously. The patient’s pretreatment body weight should be obtained for calculation of correct dosage. The dosage of aminoglycosides in obese patients should be based on an estimate of the lean body mass. It is desirable to limit the duration of treatment with aminoglycosides to short term.

DOSAGE FOR PATIENTS WITH NORMAL RENAL FUNCTION

Children: 6 to 7.5 mg/kg/day. (2 to 2.5 mg/kg administered every 8 hours.)

It is desirable to measure periodically both peak and trough serum concentrations of gentamicin when feasible during therapy to assure adequate but not excessive drug levels. For example, the peak concentration (at 30 to 60 minutes after intramuscular injection) is expected to be in the range of 3 to 5 mcg/mL. When monitoring peak concentrations after intramuscular or intravenous administration, dosage should be adjusted so that prolonged levels above 12 mcg/mL are avoided. When monitoring trough concentrations (just prior to the next dose), dosage should be adjusted so that levels above 2 mcg/mL are avoided. Determination of the adequacy of a serum level for a particular patient must take into consideration the susceptibility of the causative organism, the severity of the infection, and the status of the patient’s host-defense mechanisms.

In patients with extensive burns, altered pharmacokinetics may result in reduced serum concentrations of aminoglycosides. In such patients treated with gentamicin, measurement of serum concentrations is recommended as a basis for dosage adjustment.

The usual duration of treatment is 7 to 10 days. In difficult and complicated infections, a longer course of therapy may be necessary. In such cases monitoring of renal, auditory, and vestibular functions is recommended, since toxicity is more apt to occur with treatment extended for more than 10 days. Dosage should be reduced if clinically indicated.

For Intravenous Administration

The intravenous administration of gentamicin may be particularly useful for treating patients with bacterial septicemia or those in shock. It may also be the preferred route of administration for some patients with congestive heart failure, hematologic disorders, severe burns, or those with reduced muscle mass.

For intermittent intravenous administration, a single dose of Gentamicin Injection may be diluted in 0.9% Sodium Chloride Injection or in 5% Dextrose Injection. The solution may be infused over a period of one-half to two hours.

The recommended dosage for intravenous and intramuscular administration is identical.

Gentamicin Injection should not be physically premixed with other drugs, but should be administered separately in accordance with the recommended route of administration and dosage schedule.

DOSAGE FOR PATIENTS WITH IMPAIRED RENAL FUNCTION

Dosage must be adjusted in patients with impaired renal function to assure therapeutically adequate but
not excessive, blood levels. Whenever possible, serum concentrations of gentamicin should be monitored. One method of dosage adjustment is to increase the interval between administration of the usual doses. Since the serum creatinine concentration has a high correlation with the serum half-life of gentamicin, this laboratory test may provide guidance for adjustment of the interval between doses. In adults, the interval between doses (in hours) may be approximated by multiplying the serum creatinine level (mg/100 mL) by 8. For example, a patient weighing 60 kg with a serum creatinine level of 2 mg/100 mL could be given 60 mg (1 mg/kg) every 16 hours (2 x 8). These guidelines may be considered when treating children with serious renal impairment.

In patients with serious systemic infections and renal impairment, it may be desirable to administer the antibiotic more frequently but in reduced dosage. In such patients, serum concentrations of gentamicin should be measured so that adequate but not excessive levels result.

A peak and trough concentration measured intermittently during therapy will provide optimal guidance for adjusting dosage. After the usual initial dose, a rough guide for determining reduced dosage at eight-hour intervals is to divide the normally recommended dose by the serum creatinine level (Table 3). For example, after an initial dose of 20 mg (2 mg/kg), a child weighing 10 kg with a serum creatinine level of 2 mg/100 mL could be given 10 mg every eight hours (20 ÷ 2). It should be noted that the status of renal function may be changing over the course of the infectious process. It is important to recognize that deteriorating renal function may require a greater reduction in dosage than that specified in the above guidelines for patients with stable renal impairment.

### TABLE 3

**DOSAGE ADJUSTMENT GUIDE FOR PATIENTS WITH RENAL IMPAIRMENT**

(Dosage at Eight-Hour Intervals After the Usual Initial Dose)

<table>
<thead>
<tr>
<th>Serum Creatinine (mg %)</th>
<th>Approximate Creatinine Clearance Rate (mL/min/1.73 m²)</th>
<th>Percent of Usual Doses Shown Above</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤1</td>
<td>&gt;100</td>
<td>100</td>
</tr>
<tr>
<td>1.1 to 1.3</td>
<td>70 to 100</td>
<td>80</td>
</tr>
<tr>
<td>1.4 to 1.6</td>
<td>55 to 70</td>
<td>65</td>
</tr>
<tr>
<td>1.7 to 1.9</td>
<td>45 to 55</td>
<td>55</td>
</tr>
</tbody>
</table>
In patients with renal failure undergoing hemodialysis, the amount of gentamicin removed from the blood may vary depending upon several factors including the dialysis method used. An eight-hour hemodialysis may reduce serum concentrations of gentamicin by approximately 50%. In children, the recommended dose at the end of each dialysis period is 2 to 2.5 mg/kg depending upon the severity of the infection.

The above dosage schedules are not intended as rigid recommendations but are provided as guides to dosage when the measurement of gentamicin serum levels is not feasible.

A variety of methods are available to measure gentamicin concentrations in body fluids; these include microbiologic, enzymatic and radioimmunoassay techniques.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

**HOW SUPPLIED:**

Gentamicin Injection, USP (Preserved) is supplied as:

<table>
<thead>
<tr>
<th>2 to 2.2</th>
<th>40 to 45</th>
<th>50</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.3 to 2.5</td>
<td>35 to 40</td>
<td>40</td>
</tr>
<tr>
<td>2.6 to 3</td>
<td>30 to 35</td>
<td>35</td>
</tr>
<tr>
<td>3.1 to 3.5</td>
<td>25 to 30</td>
<td>30</td>
</tr>
<tr>
<td>3.6 to 4</td>
<td>20 to 25</td>
<td>25</td>
</tr>
<tr>
<td>4.1 to 5.1</td>
<td>15 to 20</td>
<td>20</td>
</tr>
<tr>
<td>5.2 to 6.6</td>
<td>10 to 15</td>
<td>15</td>
</tr>
<tr>
<td>6.7 to 8</td>
<td>&lt;10</td>
<td>10</td>
</tr>
</tbody>
</table>
### Product No. | NDC No. | Strength | Description
---|---|---|---
51302 | 63323-513-02 | 20 mg per 2 mL (10 mg per mL) | 2 mL multiple dose vial, packaged in 25.

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

### REFERENCES:

Lake Zurich, IL 60047

www.fresenius-kabi.us

451141C

Revised: October 2015

**PACKAGE LABEL** - **PRINCIPAL DISPLAY** - Gentamicin 2 mL Multiple Dose Vial Label

**Gentamicin Injection, USP**

**20 mg/2 mL** * (10 mg/mL)

Contains Preservative

For IM or IV Use.

Must be diluted for IV use.

**2 mL** Multiple Dose Vial
GENTAMICIN INJECTION, USP

20 mg/2 mL* (10 mg/mL)
Contains Preservative
For IM or IV Use.
Must be diluted for IV use.
2 mL Multiple Dose Vial

PACKAGE LABEL - PRINCIPAL DISPLAY - Gentamicin 2 mL Multiple Dose Vial Tray Label

NDC 63323-513-02

51302

Gentamicin Injection, USP

20 mg/2 mL* (10 mg/mL)
Contains Preservative
For IM or IV Use.
Must be diluted for IV use.
Rx only

2 mL Multiple Dose Vial
### Product Information

**Product Type**: HUMAN PRESCRIPTION DRUG  
**Item Code (Source)**: NDC:63323-513

**Route of Administration**: INTRAMUSCULAR, INTRAVENOUS

### Active Ingredient/Active Moiety

| Ingredient Name | Basis of Strength | Strength  
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>GENTAMICIN SULFATE (UNII: 8X7386QRLV) (GENTAMICIN - UNII:T6Z9V48IKG)</td>
<td>GENTAMICIN</td>
<td>10 mg in 1 mL</td>
</tr>
</tbody>
</table>

### Inactive Ingredients

| Ingredient Name | Strength  
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>METHYLPARABEN (UNII: A2I8C7HI9T)</td>
<td>1.3 mg in 1 mL</td>
</tr>
<tr>
<td>PROPYLEPARABEN (UNII: Z8IX2SCIOH)</td>
<td>0.2 mg in 1 mL</td>
</tr>
<tr>
<td>SODIUM METABISULFITE (UNII: 4VON5FNS3C)</td>
<td>3.2 mg in 1 mL</td>
</tr>
<tr>
<td>EDETATE DISODIUM (UNII: 7FLD91C86K)</td>
<td>0.1 mg in 1 mL</td>
</tr>
<tr>
<td>SULFURIC ACID (UNII: O40UQP6WCF)</td>
<td></td>
</tr>
<tr>
<td>SODIUM HYDROXIDE (UNII: 55X04QC32I)</td>
<td></td>
</tr>
</tbody>
</table>

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:63323-513-02</td>
<td>25 in 1 TRAY</td>
<td>03/04/1982</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>2 mL in 1 VIAL, MULTI-DOSE; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA</td>
<td>ANDA062356</td>
<td>03/04/1982</td>
<td></td>
</tr>
</tbody>
</table>

**Labeler**: Fresenius Kabi USA, LLC (608775388)

**Establishment**

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fresenius Kabi USA, LLC</td>
<td>840771732</td>
<td>MANUFACTURE(63323-513)</td>
<td></td>
</tr>
</tbody>
</table>

**Revised**: 11/2015